RxDoctor Payments Data

Ian del Conde Pozzi, MD

Cardiovascular Disease · Miami, FLNPI 1649309139

Payments from drug & device makers

$274,639in general payments, 2019–2025

Across 387 payments — averaging $709.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$165K
  • Bayer$32K
  • Abbott$30K
  • Pfizer$19K
  • E.r. Squibb & Sons, L.L.C.$11K
  • Boston Scientific$9K
  • plus $9K from 22 others

What the payments were for

  • Consulting fees$32,76013%
  • Speaking & faculty fees$180,22974%
  • Travel & lodging$17,8357%
  • Food & beverage$12,3005%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$274,639 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$188,065
Medicare patients
1,675
Services billed
2,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban446$491,578
XareltoRivaroxaban209$231,144
EntrestoSacubitril/Valsartan99$109,788
JardianceEmpagliflozin74$88,399
FarxigaDapagliflozin Propanediol67$58,904
Repatha SureclickEvolocumab26$28,829
Praluent PenAlirocumab17$15,798
BrilintaTicagrelor14$12,272
Rosuvastatin Calcium368$4,381
Metoprolol Succinate290$3,479
Ezetimibe102$2,615
Atorvastatin Calcium251$2,547
Bumetanide123$2,402
Losartan Potassium233$1,972
Ranolazine ErRanolazine12$1,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18,521$491,578446 claims
Johnson & JohnsonXarelto$164,614$231,144209 claims
NovartisEntresto$180$109,78899 claims
Boehringer IngelheimJardiance$62$88,39974 claims
AstraZenecaFarxiga, Brilinta$37$71,17681 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →